Validation of the composite laryngeal recurrence staging system
Validation of the composite laryngeal recurrence staging system
复制标题
DOI：
10.1002/cncr.20438
复制
发表时间：
2004-08-15
期刊：
影响因子：
6.2
通讯作者：
Piccirillo, JF
中科院分区：
文献类型：
--
作者：
Lacy, PD;Kennedy, JT;Piccirillo, JF
背景复合喉复发分期系统（CLRSS）最近已被描述为一种改进的替代再治疗TNM系统（rTNM）分期复发性喉鳞状细胞癌患者。本研究的目的是验证CLRSS并将其与rTNM系统进行比较。回顾性分析了1980年至1992年期间接受初次治疗的67例复发性喉鳞状细胞癌患者。CLRSS的外部效度进行了评估，并将其对患者分期和预测生存的能力与rTNM系统进行了比较。总体2年生存率为51%（67例患者中的34例）。rTNM系统无法对12例患者（18%）进行分期，而所有患者均可使用CLRSS进行分期。CLRSS预测生存率优于rTNM系统（c-statistic = 0.79）。新的CLRSS复发性喉癌分期系统在对更多患者进行分期和预测生存率方面优于rTNM系统。Cancer 2004;101：761-7. (C)2004年美国癌症协会。
BACKGROUND. The Composite Laryngeal Recurrence Staging System (CLRSS) has been described recently as an improved alternative to the retreatment TNM system (rTNM) for staging patients with recurrent laryngeal squamous cell carcinoma. 'the objectives of this study were to validate the CLRSS and compare its use with the rTNM system.METHODS. A retrospective chart review was conducted of 67 patients with recurrent laryngeal squamous Cell carcinoma who had their initial treatment between 1980 and 1992. The external validity of the CLRSS was assessed, and its ability to stage patients and to predict survival was compared with the rTNM system.RESULTS. The overall 2-year Survival rate was 51% (34 of 67 patients). The rTNM system was unable to stage 12 patients (18%), whereas all patients could be staged using the CLRSS. The CLRSS predicted survival better than the rTNM system (c-statistic = 0.79).CONCLUSIONS. The newer CLRSS staging system for recurrent laryngeal carcinoma outperformed the rTNM system in its ability to stage more patients and to predict survival. Cancer 2004;101:761-7. (C) 2004 American Cancer Society.